Kindred Biosciences (KIN) Rating Increased to Hold at BidaskClub
Kindred Biosciences (NASDAQ:KIN) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.
Several other brokerages have also issued reports on KIN. CL King assumed coverage on shares of Kindred Biosciences in a report on Wednesday, December 27th. They set a “neutral” rating on the stock. Zacks Investment Research lowered shares of Kindred Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine lowered shares of Kindred Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. HC Wainwright set a $11.00 price target on shares of Kindred Biosciences and gave the stock a “buy” rating in a report on Friday. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Kindred Biosciences in a report on Friday, December 22nd. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Kindred Biosciences currently has an average rating of “Hold” and a consensus target price of $9.79.
Shares of Kindred Biosciences (KIN) traded up $0.25 during mid-day trading on Friday, reaching $9.15. 175,825 shares of the company traded hands, compared to its average volume of 62,710. The stock has a market capitalization of $250.88, a price-to-earnings ratio of -7.44 and a beta of 0.05. Kindred Biosciences has a 12 month low of $5.90 and a 12 month high of $9.80.
In other Kindred Biosciences news, Director Raymond Townsend sold 6,419 shares of Kindred Biosciences stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $9.45, for a total value of $60,659.55. Following the transaction, the director now directly owns 18,419 shares of the company’s stock, valued at $174,059.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 19.10% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the company. Nationwide Fund Advisors acquired a new stake in shares of Kindred Biosciences during the second quarter worth $100,000. SG Americas Securities LLC acquired a new stake in shares of Kindred Biosciences during the third quarter worth $123,000. The Manufacturers Life Insurance Company lifted its stake in shares of Kindred Biosciences by 18,470.3% during the second quarter. The Manufacturers Life Insurance Company now owns 18,756 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 18,655 shares during the period. Trexquant Investment LP lifted its stake in shares of Kindred Biosciences by 88.6% during the third quarter. Trexquant Investment LP now owns 26,228 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 12,325 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Kindred Biosciences during the second quarter worth $306,000. Institutional investors and hedge funds own 66.61% of the company’s stock.
WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/03/03/kindred-biosciences-kin-rating-increased-to-hold-at-bidaskclub.html.
About Kindred Biosciences
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.